PMC:7299399 / 19337-20231 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T89","span":{"begin":199,"end":203},"obj":"Body_part"},{"id":"T90","span":{"begin":213,"end":217},"obj":"Body_part"},{"id":"T91","span":{"begin":240,"end":245},"obj":"Body_part"},{"id":"T92","span":{"begin":659,"end":662},"obj":"Body_part"}],"attributes":[{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma67122"},{"id":"A90","pred":"fma_id","subj":"T90","obj":"http://purl.org/sig/ont/fma/fma67122"},{"id":"A91","pred":"fma_id","subj":"T91","obj":"http://purl.org/sig/ont/fma/fma67264"},{"id":"A92","pred":"fma_id","subj":"T92","obj":"http://purl.org/sig/ont/fma/fma74412"}],"text":"On March 16, 2020, Moderna, through a partnership with the Vaccine Research Center at the U.S. National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T192","span":{"begin":36,"end":37},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T193","span":{"begin":163,"end":164},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T194","span":{"begin":188,"end":195},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T195","span":{"begin":250,"end":251},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T196","span":{"begin":378,"end":380},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T197","span":{"begin":657,"end":658},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T198","span":{"begin":716,"end":719},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T199","span":{"begin":757,"end":768},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10141"},{"id":"T200","span":{"begin":782,"end":783},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T201","span":{"begin":842,"end":845},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T202","span":{"begin":862,"end":869},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T203","span":{"begin":873,"end":879},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"On March 16, 2020, Moderna, through a partnership with the Vaccine Research Center at the U.S. National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T128","span":{"begin":240,"end":245},"obj":"Chemical"},{"id":"T129","span":{"begin":246,"end":249},"obj":"Chemical"},{"id":"T130","span":{"begin":619,"end":621},"obj":"Chemical"},{"id":"T131","span":{"begin":659,"end":662},"obj":"Chemical"}],"attributes":[{"id":"A128","pred":"chebi_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"},{"id":"A129","pred":"chebi_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A130","pred":"chebi_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A131","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"}],"text":"On March 16, 2020, Moderna, through a partnership with the Vaccine Research Center at the U.S. National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T84","span":{"begin":0,"end":94},"obj":"Sentence"},{"id":"T85","span":{"begin":95,"end":656},"obj":"Sentence"},{"id":"T86","span":{"begin":657,"end":894},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"On March 16, 2020, Moderna, through a partnership with the Vaccine Research Center at the U.S. National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"284","span":{"begin":611,"end":621},"obj":"Gene"},{"id":"285","span":{"begin":92,"end":93},"obj":"Gene"},{"id":"286","span":{"begin":145,"end":157},"obj":"Species"},{"id":"287","span":{"begin":364,"end":376},"obj":"Species"},{"id":"288","span":{"begin":748,"end":752},"obj":"Species"},{"id":"289","span":{"begin":757,"end":768},"obj":"Species"},{"id":"290","span":{"begin":873,"end":879},"obj":"Species"},{"id":"291","span":{"begin":240,"end":245},"obj":"Chemical"}],"attributes":[{"id":"A285","pred":"tao:has_database_id","subj":"285","obj":"Gene:43740568"},{"id":"A286","pred":"tao:has_database_id","subj":"286","obj":"Tax:9606"},{"id":"A287","pred":"tao:has_database_id","subj":"287","obj":"Tax:9606"},{"id":"A288","pred":"tao:has_database_id","subj":"288","obj":"Tax:10090"},{"id":"A289","pred":"tao:has_database_id","subj":"289","obj":"Tax:10141"},{"id":"A290","pred":"tao:has_database_id","subj":"290","obj":"Tax:9606"},{"id":"A291","pred":"tao:has_database_id","subj":"291","obj":"MESH:D008055"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"On March 16, 2020, Moderna, through a partnership with the Vaccine Research Center at the U.S. National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410)."}

{"project":"2_test","denotations":[{"id":"32519842-32433465-158491","span":{"begin":834,"end":836},"obj":"32433465"}],"text":"On March 16, 2020, Moderna, through a partnership with the Vaccine Research Center at the U.S. National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410)."}